Trillium Asset Management, LLC Gilead Sciences, Inc. Transaction History

Trillium Asset Management, LLC

$4 Billion
Q3 2024

A detailed history of Trillium Asset Management, LLC transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Trillium Asset Management, LLC holds 155,917 shares of GILD stock, worth $14.1 Million. This represents 0.33% of its overall portfolio holdings.

Number of Shares

155,917

Previous 161,228 3.29%

Holding current value

$14.1 Million

Previous $11.1 Million 18.14%

% of portfolio

0.33%

Previous 0.28%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 07, 2024	SELL	$66.59 - $83.99 $353,659 - $446,070	-5,311 Reduced 3.29%	155,917 $13.1 Million
Q2 2024 Aug 07, 2024	SELL	$63.15 - $72.88 $183,198 - $211,424	-2,901 Reduced 1.77%	161,228 $11.1 Million
Q1 2024 May 09, 2024	BUY	$71.58 - $87.29 $2.35 Million - $2.86 Million	32,792 Added 24.97%	164,129 $12 Million
Q4 2023 Feb 08, 2024	SELL	$73.27 - $83.09 $26,670 - $30,244	-364 Reduced 0.28%	131,337 $10.6 Million
Q3 2023 Nov 07, 2023	SELL	$73.94 - $80.67 $106,103 - $115,761	-1,435 Reduced 1.08%	131,701 $9.87 Million
Q2 2023 Aug 09, 2023	BUY	$76.01 - $86.7 $2.84 Million - $3.24 Million	37,396 Added 39.06%	133,136 $10.3 Million
Q1 2023 May 08, 2023	BUY	$77.31 - $88.08 $1,005 - $1,145	13 Added 0.01%	95,740 $7.94 Million
Q4 2022 Feb 07, 2023	SELL	$62.32 - $89.47 $296,643 - $425,877	-4,760 Reduced 4.74%	95,727 $8.22 Million
Q3 2022 Nov 09, 2022	SELL	$59.54 - $68.01 $80,914 - $92,425	-1,359 Reduced 1.33%	100,487 $6.2 Million
Q2 2022 Aug 08, 2022	SELL	$57.72 - $65.01 $289,581 - $326,155	-5,017 Reduced 4.69%	101,846 $6.3 Million
Q1 2022 May 04, 2022	SELL	$57.92 - $72.58 $5.7 Million - $7.15 Million	-98,480 Reduced 47.96%	106,863 $6.35 Million
Q4 2021 Feb 08, 2022	BUY	$64.88 - $73.64 $173,099 - $196,471	2,668 Added 1.32%	205,343 $14.9 Million
Q3 2021 Nov 12, 2021	BUY	$67.69 - $73.03 $416,496 - $449,353	6,153 Added 3.13%	202,675 $14.2 Million
Q2 2021 Aug 06, 2021	BUY	$63.47 - $69.35 $25,832 - $28,225	407 Added 0.21%	196,522 $13.5 Million
Q1 2021 May 10, 2021	BUY	$60.0 - $68.46 $28,980 - $33,066	483 Added 0.25%	196,115 $12.7 Million
Q4 2020 Feb 12, 2021	SELL	$56.65 - $64.55 $1.77 Million - $2.02 Million	-31,327 Reduced 13.8%	195,632 $11.4 Million
Q3 2020 Nov 09, 2020	SELL	$62.1 - $78.08 $108,985 - $137,030	-1,755 Reduced 0.77%	226,959 $14.3 Million
Q2 2020 Aug 06, 2020	SELL	$72.34 - $84.0 $1.52 Million - $1.77 Million	-21,064 Reduced 8.43%	228,714 $17.6 Million
Q1 2020 May 07, 2020	BUY	$62.63 - $80.22 $654,107 - $837,817	10,444 Added 4.36%	249,778 $18.7 Million
Q4 2019 Feb 10, 2020	SELL	$61.62 - $67.78 $1.9 Million - $2.09 Million	-30,800 Reduced 11.4%	239,334 $15.6 Million
Q3 2019 Nov 06, 2019	BUY	$62.51 - $69.0 $7.03 Million - $7.76 Million	112,436 Added 71.3%	270,134 $17.1 Million
Q2 2019 Aug 08, 2019	SELL	$61.87 - $69.38 $1 Million - $1.13 Million	-16,235 Reduced 9.33%	157,698 $10.7 Million
Q1 2019 May 06, 2019	BUY	$62.53 - $70.05 $12,193 - $13,659	195 Added 0.11%	173,933 $11.3 Million
Q4 2018 Feb 08, 2019	SELL	$60.54 - $79.0 $115,631 - $150,890	-1,910 Reduced 1.09%	173,738 $10.9 Million
Q3 2018 Nov 09, 2018	BUY	$71.28 - $78.92 $2.01 Million - $2.23 Million	28,213 Added 19.14%	175,648 $13.6 Million
Q2 2018 Aug 01, 2018	BUY	$64.88 - $75.68 $4.79 Million - $5.58 Million	73,759 Added 100.11%	147,435 $10.4 Million
Q1 2018 May 09, 2018	BUY	$72.84 - $88.8 $925,650 - $1.13 Million	12,708 Added 20.84%	73,676 $5.55 Million
Q4 2017 Feb 01, 2018	SELL	$71.15 - $83.52 $50,445 - $59,215	-709 Reduced 1.15%	60,968 $4.37 Million
Q3 2017 Nov 02, 2017	BUY	$72.11 - $85.47 $4.45 Million - $5.27 Million	61,677	61,677 $5 Million

Others Institutions Holding GILD

# of Institutions

1,923

Shares Held

994M

Call Options Held

10.5M

Put Options Held

9.75M

View Full List

About GILEAD SCIENCES, INC.

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $113B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

More about GILD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Trillium Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Trillium Asset Management, LLC with notifications on news.

Account

Trillium Asset Management, LLC Gilead Sciences, Inc. Transaction History